Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In 2025, three wholesalers individually comprised approximately 43%, 36%, and 20%, respectively, of our total gross product revenue from continuing operations.”
$42M relationship
basisCHRS fy2025 · closed 2025-12 $42M
FILING10-K0001104659-26-025308cik 0001512762
“Junshi Biosciences is responsible for supplying us with drug substance and final drug products.”
FILING10-K0001104659-26-025308cik 0001512762
“Under the terms of the supply agreement, Coherus will provide LOQTORZI for a planned Phase 3 clinical trial.”
FILING10-K0001055726-26-000008cik 0001055726disclosed by INO
“On June 27, 2024, we entered into a license Agreement with Apotex, pursuant to which, we granted to Apotex the Canada License Agreement.”
FILING10-K0001104659-26-025308cik 0001512762
“In December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize antibodies that target PVRIG, including the antibody GSK4381562 (the "Licensed Antibodies").”
FILING10-K0001104659-26-025308cik 0001512762
“Intas has designated Accord to purchase the physical assets, including product inventory.”
FILING10-K0001104659-26-025308cik 0001512762
“The first such payment is payable by Intas to us if Net Sales of UDENYCA for four consecutive fiscal quarters from July 1, 2025 through September 30, 2026 are equal to or greater than $300 million, and the second such payment is payable by Intas to the Company if Net Sales of UDENYCA for four consecutive fiscal quarters from July 1, 2025 through March 31, 2027 are equal to or greater than $350 million.”
FILING10-K0001104659-26-025308cik 0001512762
“On February 4, 2026, we announced a clinical supply agreement with Janssen Research & Development, LLC, to evaluate tagmokitug in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer.”
FILING10-K0001104659-26-025308cik 0001512762
Watchlist prices, news filtered to it, and its next report on your desk.
Coherus Oncology, Inc. has 3 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Coherus Oncology, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
CHRS (Coherus Oncology, Inc.) has 3 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: GSK +0.76%, in industrials & materials.
Prev close 1.34 · gapped below the open, never looked back. High/low 1.33 at 4:00 am ET, 1.33 at 4:00 am ET.
Coherus Oncology, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)